Studies
Locally Advanced Cervical Cancer- High-Risk Study
Coming SoonPatient Recruitment Initiation: 2026
Overview
A Phase II single-arm open-label study of pembrolizumab and Lenvatinib in patients with high-risk locally advanced cervix cancer-EMBRACE High Risk Initiative
Lead Investigators
RN
Remi A Nout
Erasmus University Medical Centre
SC
Supriya Chopra
ACTREC, Tata Memorial Centre
IB
Ingrid Boere
Erasmus University Medical Centre